Barclays PLC Aravive, Inc. Transaction History

Barclays PLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$2.19 - $4.07 $3,674 - $6,829	-1,678 Closed	0 $0
Q3 2021 Nov 09, 2021	SELL	$3.67 - $5.8 $5,314 - $8,398	-1,448 Reduced 46.32%	1,678 $6,000
Q2 2021 Aug 13, 2021	SELL	$4.65 - $6.42 $32,726 - $45,183	-7,038 Reduced 69.24%	3,126 $19,000
Q1 2021 May 13, 2021	BUY	$5.11 - $9.24 $31,886 - $57,657	6,240 Added 159.02%	10,164 $67,000
Q4 2020 Feb 11, 2021	SELL	$4.36 - $6.51 $7,154 - $10,682	-1,641 Reduced 29.49%	3,924 $22,000
Q3 2020 Nov 12, 2020	SELL	$4.7 - $12.06 $5,212 - $13,374	-1,109 Reduced 16.62%	5,565 $27,000
Q2 2020 Aug 12, 2020	BUY	$5.18 - $14.81 $34,571 - $98,841	6,674 New	6,674 $78,000
Q1 2020 May 13, 2020	SELL	$3.5 - $13.77 $3 - $13	-1 Closed	0 $0
Q4 2019 Feb 10, 2020	SELL	$6.21 - $14.02 $235 - $532	-38 Reduced 97.44%	1 $0
Q4 2018 Feb 14, 2019	BUY	$3.23 - $8.7 $125 - $339	39 New	39 $0

28.1K

Ticker ARAV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,518,300
Description
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of pl...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.